Meeder Asset Management’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-96
| Closed | -$1K | – | 2416 |
|
|
2020
Q3 | $1K | Hold |
96
| – | – | ﹤0.01% | 2103 |
|
|
2020
Q2 | $1K | Sell |
96
-371
| -79% | -$2.84K | ﹤0.01% | 1993 |
|
|
2020
Q1 | $3K | Buy |
+467
| New | +$4.11K | ﹤0.01% | 2036 |
|
|
2019
Q4 | – | Sell |
-476
| Closed | -$5K | – | 2503 |
|
|
2019
Q3 | $5K | Sell |
476
-342
| -42% | -$3.6K | ﹤0.01% | 1795 |
|
|
2019
Q2 | $8K | Sell |
818
-905
| -53% | -$9.76K | ﹤0.01% | 1542 |
|
|
2019
Q1 | $22K | Sell |
1,723
-5,849
| -77% | -$87.1K | ﹤0.01% | 1061 |
|
|
2018
Q4 | $114K | Sell |
7,572
-439
| -5% | -$8.37K | 0.01% | 606 |
|
|
2018
Q3 | $160K | Sell |
8,011
-936
| -10% | -$21.3K | 0.01% | 535 |
|
|
2018
Q2 | $174K | Buy |
8,947
+7,652
| +591% | +$169K | 0.02% | 532 |
|
|
2018
Q1 | $26K | Sell |
1,295
-106
| -8% | -$1.79K | ﹤0.01% | 826 |
|
|
2017
Q4 | $18K | Buy |
1,401
+366
| +35% | +$5.52K | ﹤0.01% | 958 |
|
|
2017
Q3 | $19K | Buy |
1,035
+226
| +28% | +$4.21K | ﹤0.01% | 919 |
|
|
2017
Q2 | $15K | Buy |
809
+773
| +2,147% | +$15.3K | ﹤0.01% | 895 |
|
|
2017
Q1 | $1K | Buy |
+36
| New | +$862 | ﹤0.01% | 1596 |
|
|
2016
Q2 | – | Sell |
-3,286
| Closed | -$77K | – | 985 |
|
|
2016
Q1 | $77K | Sell |
3,286
-1,460
| -31% | -$34.7K | 0.01% | 711 |
|
|
2015
Q4 | $143K | Buy |
4,746
+2,527
| +114% | +$81.6K | 0.01% | 579 |
|
|
2015
Q3 | $88K | Sell |
2,219
-36,644
| -94% | -$2.27M | 0.01% | 607 |
|
|
2015
Q2 | $2.68M | Buy |
+38,863
| New | +$2.44M | 0.27% | 87 |
|
Meeder Asset Management's AMAG Position: Q4 2020 in Review
Meeder Asset Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 96 shares — an estimated $1K sold.
Meeder Asset Management first reported a position in AMAG in Q2 2015 and held it in 18 quarters. The position peaked at $2.68M in Q2 2015. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Meeder Asset Management reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Meeder Asset Management sold 96 AMAG Pharmaceuticals shares in Q4 2020, an estimated $1K.
- Meeder Asset Management first reported a position in AMAG Pharmaceuticals in Q2 2015 and held it in 18 quarters.
- Meeder Asset Management's AMAG Pharmaceuticals position peaked at $2.68M in Q2 2015.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.